Molecular mechanisms of L-DOPA-induced dyskinesiaJENNER, Peter.Nature reviews. Neuroscience (Print). 2008, Vol 9, Num 9, pp 665-677, issn 1471-003X, 13 p.Article

A_2A antagonists as novel nondopaminergic therapy for motor dysfunction in PDJENNER, Peter.Neurology. 2003, Vol 61, Num 11, pp S32-S38, issn 0028-3878, SUP6Article

Pharmacology of dopamine agonists in the treatment of Parkinson's diseaseJENNER, Peter.Neurology. 2002, Vol 58, Num 4, pp S1-S8, issn 0028-3878, SUP1Article

Explaining ADAGIO: A Critical Review of the Biological Basis for the Clinical Effects of RasagilineJENNER, Peter; LANGSTON, J. William.Movement disorders. 2011, Vol 26, Num 13, pp 2316-2323, issn 0885-3185, 8 p.Article

A novel dopamine agonist for the transdermal treatment of Parkinson's diseaseJENNER, Peter.Neurology. 2005, Vol 65, Num 2, pp S3-S5, issn 0028-3878, SUP1Article

Women into energy and engineering : diversifyibg the workforceJENNER, Peter; LEWIS, Lisa.Energy world (Monthly). 2001, Num 285, pp 16-17, issn 0307-7942Article

The distribution of copper, zinc- and manganese-superoxide dismutase, and glutathione peroxidase messenger ribonucleic acid in rat basal gangliaKUNIKOWSKA, Grazyna; JENNER, Peter.Biochemical pharmacology. 2002, Vol 63, Num 6, pp 1159-1164, issn 0006-2952Article

Etiology and Pathogenesis of Parkinson's DiseaseSCHAPIRA, Anthony H; JENNER, Peter.Movement disorders. 2011, Vol 26, Num 6, pp 1049-1055, issn 0885-3185, 7 p.Article

6-Hydroxydopamine-lesioning of the nigrostriatal pathway in rats alters basal ganglia mRNA for copper, zinc- and manganese-superoxide dismutase, but not glutathione peroxidaseKUNIKOWSKA, Grazyna; JENNER, Peter.Brain research. 2001, Vol 922, Num 1, pp 51-64, issn 0006-8993Article

Avoidance of dyskinesia: Preclinical evidence for continuous dopaminergic stimulationJENNER, Peter.Neurology. 2004, Vol 62, Num 1, pp S47-S55, issn 0028-3878, SUP1Article

Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's diseaseJENNER, Peter.Neurology. 2004, Vol 63, Num 7, pp S13-S22, issn 0028-3878, SUP2Article

Alterations in m-RNA expression for Cu, Zn-superoxide dismutase and glutathione peroxidase in the basal ganglia of MPTP-treated marmosets and patients with Parkinson's diseaseKUNIKOWSKA, Grazyna; JENNER, Peter.Brain research. 2003, Vol 968, Num 2, pp 206-218, issn 0006-8993, 13 p.Article

The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of L-dopa in unilaterally 6-OHDA-lesioned ratsROSE, Sarah; RAMSAY CROFT, Neil; JENNER, Peter et al.Brain research. 2007, Vol 1133, pp 110-114, issn 0006-8993, 5 p.Article

The MPTP-treated primate as a model of motor complications in PD: Primate model of motor complicationsJENNER, Peter.Neurology. 2003, Vol 61, Num 6, pp 4-11, issn 0028-3878, 8 p., SUP3Article

Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the diseaseDUTY, Susan; JENNER, Peter.British journal of pharmacology. 2011, Vol 164, Num 4, pp 1357-1391, issn 0007-1188, 35 p.Article

Expression of integrin and CD44 receptors recognising osteopontin in the normal and LPS-lesioned rat substantia nigraAILANE, Sara; LONG, Philip; JENNER, Peter et al.European journal of neuroscience (Print). 2013, Vol 38, Num 3-4, pp 2468-2476, issn 0953-816X, 9 p.Article

Endogenous dopaminergic tone and dopamine agonist actionTRESEDER, Sarah A; SMITH, Lance A; JENNER, Peter et al.Movement disorders. 2000, Vol 15, Num 5, pp 804-812, issn 0885-3185Article

Cell death and neuroprotection in Parkinson's diseaseOLANOW, C. Warren; JENNER, Peter; BEAL, M. Flint et al.Annals of neurology. 1998, Vol 44, Num 3, issn 0364-5134, 201 p., SUP1Conference Proceedings

The pathogenesis of cell death in Parkinson's diseaseJENNER, Peter; OLANOW, C. Warren.Neurology. 2006, Vol 66, Num 10, issn 0028-3878, S24-S36, SUP4Article

Proteasomal function is impaired in substantia nigra in Parkinson's diseaseMCNAUGHT, Kevin St. P; JENNER, Peter.Neuroscience letters. 2001, Vol 297, Num 3, pp 191-194, issn 0304-3940Article

Functional Models of Parkinson's Disease : A Valuable Tool in the Development of Novel TherapiesJENNER, Peter.Annals of neurology. 2008, Vol 64, Num 6, issn 0364-5134, S16-S29, SUPArticle

Osteopontin expression in activated glial cells following mechanical-or toxin-induced nigral dopaminergic cell lossICZKIEWICZ, Joanna; ROSE, Sarah; JENNER, Peter et al.Experimental neurology (Print). 2007, Vol 207, Num 1, pp 95-106, issn 0014-4886, 12 p.Article

Osteopontin (Eta-1) is present in the rat basal gangliaICZKIEWICZ, Joanna; ROSE, Sarah; JENNER, Peter et al.Molecular brain research. 2004, Vol 132, Num 1, pp 64-72, issn 0169-328X, 9 p.Article

Dopamine D₁ receptor expression in human basal ganglia and changes in Parkinson's diseaseHURLEY, Michael J; MASH, Deborah C; JENNER, Peter et al.Molecular brain research. 2001, Vol 87, Num 2, pp 271-279, issn 0169-328XArticle

Extracellular accumulation of nitric oxide, hydrogen peroxide, and glutamate in astrocytic cultures following glutathione depletion, complex I inhibition, and/or lipopolysaccharide-induced activationMCNAUGHT, Kevin St. P; JENNER, Peter.Biochemical pharmacology. 2000, Vol 60, Num 7, pp 979-988, issn 0006-2952Article